Educational Articles

Loading...
Accelerate your knowledge of stocks, funds, options, convertibles and the economy.  Get the most from Value Line research through must-read articles that make you a smarter investor.


Stocks / Highlights

Coverage Initiation: Northland Power Inc.

Iason Dalavagas | 9/22/2014

Value Line is initiating coverage of Northland Power Inc. (NPI.TO), a company that owns and operates power generation projects in Canada, the U.S., and Germany. The company is headquartered in Toronto, Canada, and was formed in 1987.

Read more
Markets / Commentaries
Sales of Existing Homes Stumble In August 2014

Harvey S. Katz | 9/22/2014

Sales of existing homes eased somewhat in August, falling by 1.8%, to a seasonally adjusted annualized rate of 5.05 million homes. That was less than the 5.20 million homes forecast. Of note, the July tally, originally estimated at 5.15 million homes sold, was pared back slightly to an estimated 5.14 million homes seeing transactions.

Read more
Stocks / Highlights
Using A Value Line Report: Does Chevron Have the Energy to Fuel Long Term Growth

Simon Shoucair | 9/19/2014

In this installment of Using the Value Line Report we will be taking a look at one of the Dow’s iconic energy giants, Chevron Corporation (CVX). This review will examine a few of the oil and gas company’s investment merits and offer readers some insight into how the Value Line page highlights many of the most essential financial ratios, as well as providing quantitative and qualitative analysis of both historical and projected performance.

Read more
Markets / Commentaries
Housing Starts Surprisingly Stumble In August: September 18, 2014

Harvey S. Katz, CFA | 9/18/2014

Just when it looked as though the stars were aligned once again for the housing market, some rain has been thrown on the parade. True, there was no deluge, and homebuilding in the latest month still exceeded the year-earlier total. Nevertheless, the falloff was worse than had been anticipated.

Read more
Stocks / Commentaries
Drug Roundup: September 18, 2014

Michael Ratty | 9/18/2014

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc. (PFE), AstraZeneca (AZN), Merck & Co. (MRK), AbbVie Inc. (ABBV), and Eli Lilly (LLY)

Read more
Stocks / Analyst Ideas
Stock Screen: Biggest Free Cash Flow Generators September 17, 2014

Kevin Downing | 9/17/2014

In this stock screen, Synaptics (SYNA) made our list of companies with strong free cash flow.

Read more
Stocks / Analyst Ideas
Stock Screen: Biggest Free Cash Flow Generators September 17, 2014

Kevin Downing | 9/17/2014

In this stock screen, Synaptics (SYNA) made our list of companies with strong free cash flow.

Read more
Markets / Commentaries
The Fed Stays The Course On Interest Rates

William G. Ferguson | 9/17/2014

The Federal Reserve released its much-anticipated statement following the conclusion of its two-day monetary policy meeting. The testimonial featured minimal changes from the last release, as the lead bank noted that it will keep interest rates low for a “considerable time,” much to the delight of equity market participants. The equity market moved modestly higher on the commentary, as low interest rates and a supportive Fed are typically viewed favorably by investors and that certainly seems to be the case once again today.

Read more
Stocks / Commentaries
The Dogs Lost Some Steam In The August Heat, But Maintained Their Lead

Mario Ferro | 9/16/2014

As the U.S. bull market for equities marches toward a sixth straight year, major benchmarks such as the S&P 500 and Dow Jones Industrials have clawed their ways to new highs. However, the numbers alone don’t tell the whole story. The Dogs of the Dow strategy, unsurprisingly, is also benefitting from the upswing, advancing every month with the exception of January. Although August found the pack lagging the gains posted by the 30 Dow Industrials as a whole, year-to-date performance has maintained a relatively comfortable lead. Merck and Microsoft logged the biggest gains last month, but Intel’s stock has outrun the Dogs (and the rest of the Dow components, for that matter) by a sizable margin so far this year.

Read more